Launch of new.co.uk Marketing Campaign
MedPal AI plc has launched a paid digital marketing campaign for its private weight management clinic, new.co.uk, across Meta and Google to build brand awareness and acquire patients for its GLP-1 weight management proposition. This initiative is strategically timed ahead of the anticipated UK availability of oral GLP-1 therapies, following strong US sales where Novo Nordisk's oral semaglutide has surpassed three million prescriptions since January 2026. MedPal AI believes its existing NHS Distance Selling Pharmacy infrastructure, with automated dispensing capacity, positions it well to capitalize on this growing market opportunity once regulatory approval is granted by the MHRA.
Select text to share a quote on X · sign in to keep highlights & notes in your MPAL notes
Commercial Update: new.co.uk Marketing Campaign Launch and Positioning Ahead of Anticipated UK Oral GLP-1 Availability
MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy group, is pleased to provide an update on the commercial development of its private weight management clinic, New Health, operating at new.co.uk.
Marketing campaign commenced
The Company has commenced a paid digital marketing campaign for new.co.uk across Meta and Google, supporting the build-out of New Health's GLP-1 weight management proposition. The campaign forms part of the previously announced marketing investment in the New Health platform and is designed to drive patient acquisition and brand awareness in the UK private weight management market.
Market context
The Directors believe the UK private GLP-1 weight management market continues to expand rapidly. On 7 June 2026, Novo Nordisk Inc. announced that prescriptions for the oral formulation of its semaglutide weight-loss product had surpassed three million in the United States since its launch there in January 2026, with the company reporting that more than 80% of new prescriptions were for patients new to GLP-1 therapy - indicating that oral GLP-1 therapy is expanding the treated population rather than displacing existing therapies.
An oral formulation of semaglutide for weight management is currently under review by the UK Medicines and Healthcare products Regulatory Agency (MHRA), with a regulatory decision anticipated in 2026.
Strategic positioning
MedPal operates NHS Distance Selling Pharmacy infrastructure with automated dispensing capacity across its Runcorn and Swaffham hubs. The Directors believe this dispensing infrastructure, combined with the New Health clinical platform, means that the Company is well positioned to participate in the UK oral GLP-1 weight management opportunity as and when such therapies receive UK marketing authorisation.
Jason Drummond, Founder and Chief Executive Officer of MedPal, commented:
"The scale of patient demand for GLP-1 therapy is one of the defining healthcare trends of this decade, and the data emerging from the US oral launch underlines how much of that demand is coming from people new to the treatment. We are investing now to build new.co.uk into a recognised UK brand in weight management, so that MedPal is well positioned to serve patients across both injectable and, in due course and subject to regulatory approval, oral therapies. Our pharmacy dispensing infrastructure is a genuine differentiator as this market matures."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.